Royalty Pharma plc (RPRX) — Titan Protect Analysis

RPRX

Royalty Pharma plc

Healthcare · ·

$55.87

Data: 2026-06-03

✓ ETHICAL PASS

NARROW MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$31.5B

Total market value of the company

Trailing P/E

28.79

Premium valuation

Forward P/E

9.75

Based on estimated future earnings — lower means cheaper

Rev Growth

+11.0%

Year-over-year revenue change

Profit Margin

33.9%

How much profit the company keeps from each dollar of revenue

ROE

13.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$60.00

+7% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 8 analysts covering this stock

About Royalty Pharma plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ

https://www.royaltypharma.com

Country: United States Employees: 100 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

1.788

Excellent risk-adjusted returns

Kelly Fraction

0.1425

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

2.856

Returns exceed worst-case losses — strong risk profile

Annual Return

46.7%

Historical annualised return based on price data

Max Drawdown

-16.4%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

142

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.40

Very low correlation to market moves

52W High

$56.07

0% below the year high

52W Low

$33.25

68% above the year low

Avg Volume

3,561,236

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

174.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$1.90

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

90.32

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

115.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

100.3%

Profit from core operations before interest and tax

Free Cash Flow

$-980,302,528

Negative — the business is spending more than it generates

Revenue (TTM)

$2.4B

Total revenue over the last 12 months

Net Income

$826M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$66.00

Target Median

$60.00

Target Low

$46.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go